Skip to main content

Peer Review reports

From: Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

Original Submission
29 Nov 2020 Submitted Original manuscript
18 Jan 2021 Reviewed Reviewer Report
25 Jan 2021 Reviewed Reviewer Report
16 Mar 2021 Author responded Author comments - Zahra Mirzaasgari
Resubmission - Version 2
16 Mar 2021 Submitted Manuscript version 2
3 Apr 2021 Reviewed Reviewer Report
22 Apr 2021 Author responded Author comments - Zahra Mirzaasgari
Resubmission - Version 3
22 Apr 2021 Submitted Manuscript version 3
23 Apr 2021 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
26 Apr 2021 Editorially accepted
1 May 2021 Article published 10.1186/s12883-021-02218-4

You can find further information about peer review here.

Back to article page